Form ARS Spyre Therapeutics, Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'
April 13, 2026 8:21 AM EDTLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).
The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More
Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'
April 13, 2026 7:46 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).
The analyst comments "Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). Across multiple endpoints (RHI from baseline, clinical remission, endoscopic improvement), SPY001/47 consistently outperformed TAK's Entyvio (both Week 6 & 14 comps), with most notable efficacy outcome of 40% clinical remission at week 12 (Fig 1 & 2). The induction CR data is one of the highest we have seen and significantly... More
